Novo Nordisk will launch the tablet version of its Wegovy weight-loss drug in Germany on September 1, 2026. This release marks the first oral semaglutide formulation for obesity to enter the European Union. The move follows an EU-wide authorization granted on July 15, 2026. This pill alternative represents a key strategic expansion for the company's blockbuster obesity franchise.
The launch coincides with Novo Nordisk stock trading near recent highs. The company is currently executing a DKK 15 billion share repurchase program. This 12-month buyback initiative began in February 2026. The company had repurchased more than DKK 8.7 billion in shares by late August 2026. These transactions increased treasury holdings to 1.0% of the total share capital.